Ingevity Corporation reported its financial results for the second quarter of 2025, showing a 7% decline in net sales to $365.1 million, primarily due to reduced sales in the Performance Chemicals segment. The company experienced a net loss of $146.5 million, largely impacted by a pre-tax non-cash goodwill impairment charge of $183.8 million related to the Advanced Polymer Technologies segment. This charge was attributed to heightened global trade uncertainty and its effect on industrial demand recovery forecasts. Adjusted earnings increased 39% to $51.1 million, while adjusted EBITDA rose by 9% to $110.0 million, with the EBITDA margin improving to 30.1%. These improvements were mainly due to successful repositioning actions in the Performance Chemicals segment, which led to reduced raw material costs and a better product mix. Ingevity has updated its guidance, raising the low-end of its adjusted EBITDA forecast to between $390 million and $415 million, reflecting solid results and improved expectations for North American auto production. The company maintains its full-year sales guidance of between $1.25 billion and $1.40 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.